Back to Results
First PageMeta Content
Myriad Genetics / Bevirimat / Melanoma / Glioblastoma multiforme / Hsp90 inhibitors / Brain tumor / Medicine / Cancer research


June 18, 2009 Dear Myriad Genetics, Inc. Stockholder: I am pleased to inform you that the Board of Directors of Myriad Genetics, Inc. (“Myriad Genetics”) has approved the distribution of all of the shares of common s
Add to Reading List

Document Date: 2012-10-18 13:12:14

Open Document

File Size: 450,76 KB

Share Result on Facebook

Company

Dear Myriad Genetics Inc. / Panacos Pharmaceuticals Inc. / INFORMATION STATEMENT MYRIAD PHARMACEUTICALS INC. / Dear Myriad Pharmaceuticals Inc. / Myriad Pharmaceuticals Inc. / Myriad Genetics Inc. / D. / /

Country

United States / /

Event

Judicial Event / FDA Phase / IPO / /

/

IndustryTerm

chemical class / consolidated subsidiaries / chemical lead compounds / throughput technology / management / chemical structures / pharmaceutical development experience / biopharmaceutical / treatment of HIV / chemical proteomics / treatment of both solid and blood cancers / treatment of cancer / chemical proteomic drug discovery / therapeutic products / protein-protein interaction technology / /

MedicalCondition

HIV / headache / CNS metastases / solid tumors / primary brain tumors / nausea / CNS metastasis / clinical-stage cancer / Melanoma / Anaplastic glioma / advanced primary and metastatic tumors / leukemias / human diseases / hypersensitivity / diarrhea / reduced tumor / peripheral neuropathies / primary CNS tumors / human ovarian cancer / HIV infection / tumor / cancer / broad disease / tumors / disease / brain metastases / glioblastoma multiforme / blood cancers / glioblastomas / nonfatal myocardial infarctions / stroke / melanomas / lymphomas / advanced cancer / anaplastic gliomas / moderate intensity diarrhea / each disease / refractory solid tumors / dizziness / malignant gliomas / both cancer / relapsed cancers / lightheadedness / metastatic melanoma / /

Organization

U.S. Food and Drug Administration / American Cancer Society / Securities and Exchange Commission / /

Person

Gerald Belle / John Henderson / Dennis Langer / Azixa / Robert Forrester / Adrian Hobden / Robert Lollini / Wayne Laslie / Adrian N. Hobden / /

/

Position

executive officer / Chief Financial Officer / Peter D. Meldrum President and Chief Executive Officer / Chief Operating Officer / President and Chief Executive Officer / leader in the development / Chairman of the Board / Candidate / Ph. President and Chief Executive Officer / /

Product

carboplatin / MPC-4326 / MPC-9055 / Azixa / MPC-3100 / MPI-443803 / /

Technology

drug metabolism / proteomics / protein-protein interaction technology / automated / high throughput technology / apoptosis / second technology / pharmacokinetics / drug discovery / two technologies / drug development / /

SocialTag